Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 20/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5786185 | 0.91 | NPY5R (0.74) | NPY5R | |
| SCHEMBL5788699 | 0.90 | NPY5R (0.69) | NPY5R | |
| SCHEMBL5785880 | 0.88 | NPY5R (0.68) | NPY5R | |
| SCHEMBL5786978 | 0.87 | NPY5R (0.77) | NPY5R | |
| SCHEMBL5790240 | 0.87 | NPY5R (0.85) | NPY5R | |
| SCHEMBL6453626 | 0.86 | NPY5R (0.86) | NPY5R | |
| SCHEMBL5786287 | 0.85 | NPY5R (0.77) | NPY5R | |
| SCHEMBL5786275 | 0.85 | NPY5R (0.85) | NPY5R | |
| SCHEMBL4789172 | 0.85 | NPY5R (0.85) | NPY5R | |
| SCHEMBL4788137 | 0.84 | NPY5R (1.00) | NPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1695977-A2 | Spiro [isobenzofuran-1,4'piperidin]-3-ones and 3H-spiroisobenzofuran-1, 4'-piperidines | Neurogen Corporation (US) | 2006-08-30 | — | — | EP | claimed |
| EP-1347982-B1 | SPIRO ISOBENZOFURAN-1,4'-PIPERIDIN]-3-ONES AND 3H-SPIROISOBENZOFURAN-1,4'-PIPERIDINES | NEUROGEN CORP (US) | 2005-11-16 | — | — | EP | claimed |
| US-20050033048-A1 | Spiro[isobenzofuran-1,4'-piperidin]-3-ones and 3h-spiroisobenzofuran-1,4'-piperidines | NEUROGEN CORPORATION | 2005-02-10 | — | — | US | claimed |
| US-20040072847-A1 | Spiro[isobenzofuran-1,4'-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4'-piperidines | NEUROGEN CORPORATION | 2004-04-15 | — | — | US | claimed |
| US-6566367-B2 | For therapy of eating disorders such as obesity or bulimia, psychiatric disorders, diabetes and cardiovascular disorders such as hypertension in humans, domesticated companion animals and livestock animals | PFIZER INC. | 2003-05-20 | — | — | US | claimed |
| US-20030036652-A1 | Spiro[isobenzofuran-1,4'-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4'-piperidines | NEUROGEN CORPORATION | 2003-02-20 | — | — | US | claimed |
| EP-1695977-A2 | Spiro [isobenzofuran-1,4'piperidin]-3-ones and 3H-spiroisobenzofuran-1, 4'-piperidines | Neurogen Corporation (US) | 2006-08-30 | — | — | EP | disclosed |
| US-20060040964-A1 | Spiro[isobenzofuran-1,4'-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4'-piperidines | BAKTHAVATCHALAM RAJAGOPAL | 2006-02-23 | — | — | US | disclosed |
| EP-1347982-B1 | SPIRO ISOBENZOFURAN-1,4'-PIPERIDIN]-3-ONES AND 3H-SPIROISOBENZOFURAN-1,4'-PIPERIDINES | NEUROGEN CORP (US) | 2005-11-16 | — | — | EP | disclosed |
| US-6943199-B2 | Spiro[isobenzofuran-1,4′-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4′-piperidines | NEUROGEN CORPORATION (US) | 2005-09-13 | — | — | US | disclosed |
| US-20050119285-A1 | Treatment of neurological disorders related to rapid eye movement (REM) sleep disturbances with NPY Y5 receptor antagonists | PFIZER INC | 2005-06-02 | — | — | US | disclosed |
| US-20050119283-A1 | Treatment of circadian rhythm disorders with NPY Y5 receptor antagonist | PFIZER INC | 2005-06-02 | — | — | US | disclosed |
| US-20050033048-A1 | Spiro[isobenzofuran-1,4'-piperidin]-3-ones and 3h-spiroisobenzofuran-1,4'-piperidines | NEUROGEN CORPORATION | 2005-02-10 | — | — | US | disclosed |
| US-20040072847-A1 | Spiro[isobenzofuran-1,4'-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4'-piperidines | NEUROGEN CORPORATION | 2004-04-15 | — | — | US | disclosed |
| US-6566367-B2 | For therapy of eating disorders such as obesity or bulimia, psychiatric disorders, diabetes and cardiovascular disorders such as hypertension in humans, domesticated companion animals and livestock animals | PFIZER INC. | 2003-05-20 | — | — | US | disclosed |
| US-20030036652-A1 | Spiro[isobenzofuran-1,4'-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4'-piperidines | NEUROGEN CORPORATION | 2003-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072847-A1 | Spiro[isobenzofuran-1,4'-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4'-piperidines | NPY5R, NPY4R, NPY1R | NPY5R 1/4885 |
| US-20050119283-A1 | Treatment of circadian rhythm disorders with NPY Y5 receptor antagonist | NPY5R, NPY1R, NPY2R | NPY5R 1/4885 |
| US-20050119285-A1 | Treatment of neurological disorders related to rapid eye movement (REM) sleep disturbances with NPY Y5 receptor antagonists | NPY5R, NPY1R, NPY2R | NPY5R 1/4885 |
| US-20030036652-A1 | Spiro[isobenzofuran-1,4'-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4'-piperidines | NPY5R, NPY4R, NPY1R | NPY5R 1/4885 |
| US-20060040964-A1 | Spiro[isobenzofuran-1,4'-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4'-piperidines | NPY5R, NPY4R, SSTR5 | NPY5R 1/4885 |
| US-20050033048-A1 | Spiro[isobenzofuran-1,4'-piperidin]-3-ones and 3h-spiroisobenzofuran-1,4'-piperidines | NPY5R, NPY4R, SSTR5 | NPY5R 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.